// App-Quantinova.ai

: ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS

Researchers

Presenter

  • Jean-Paul Bahary

Principal Investigators

  • John Fiveash

  • Joseph Bovi

  • Steven Howard

  • Michael Yu

  • David Dsouza

  • Nadia Laack

  • Mack Roach

  • Young Kwok

  • Daniel Wahl

  • John Stasser

  • Minhee Won

  • Minesh P Mehta

Medical Centers

  • CRCHUM, Institut du Cancer de Montreal, Montreal, QC, Canada

  • University of Alabama, Birmingham, AL

  • The Froedtert & the Medical College of Wisconsin, Milwaukee, WI

  • Moffitt Cancer Center, Tampa, FL

  • London Regional Cancer Centre, London, ON, Canada

  • University of California, San Francisco, San Francisco, CA

  • University of Michigan, Ann Arbor, MI

  • Christiana Care Health Services, Delaware, MD, USA

  • NRG Oncology, Philadelphia, PA

  • Miami Cancer Institute, Miami, FL

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved